Vertex Pharmaceuticals (VRTX) Falls
Shares of Vertex Pharmaceuticals Inc. (VRTX.O: Quote, Profile, Research) fell 3.1 percent before the opening bell on Monday after a Barron's report saying the company's shares are overvalued. The report said the company, whose shares have quadrupled on hopes its experimental hepatitis C drug will be the first to market, will ultimately face competition.
Its shares were trading down at $43.50 in electronic trade after closing at $44.90.
Source: Reuters.comLabels: drugs, pharmaceuticals, Vertex Pharmaceuticals, VRTX
posted by Stock Administrator @ 12:40 AM
Vertex Pharmaceuticals (VRTX) Falls
Shares of Vertex Pharmaceuticals Inc. (VRTX.O: Quote, Profile, Research) fell 3.1 percent before the opening bell on Monday after a Barron's report saying the company's shares are overvalued. The report said the company, whose shares have quadrupled on hopes its experimental hepatitis C drug will be the first to market, will ultimately face competition.
Its shares were trading down at $43.50 in electronic trade after closing at $44.90.
Source: Reuters.com
Its shares were trading down at $43.50 in electronic trade after closing at $44.90.
Source: Reuters.com
Labels: drugs, pharmaceuticals, Vertex Pharmaceuticals, VRTX
posted by Stock Administrator @ 12:40 AM
0 Comments:
Post a Comment
<< Home